#Norway #Oslo #Navamedic ASA #Imdur #TopRidge Pharma

Navamedic ASA Extends Distribution Agreement for Imdur®

In a significant announcement on April 29, 2025, Navamedic ASA, a prominent player in the Nordic pharmaceutical market, revealed that it has successfully renewed its distribution agreement for the widely used heart medication, Imdur®. The renewed partnership with TopRidge Pharma Limited will remain valid until June 2032, demonstrating the commitment of both companies to delivering high-quality healthcare solutions.

The agreement's extended duration also allows for the potential addition of new products, broadening the collaborative scope between Navamedic and TopRidge. CEO Kathrine Gamborg Andreassen expressed enthusiasm over the renewed collaboration, highlighting the importance of Imdur in their product portfolio, particularly in Nordic countries, the Netherlands, the Baltics, Greece, and Cyprus.

Imdur® is known for its effectiveness in preventing angina pectoris, a common condition associated with heart disease. Launched in Europe in 1985, this prescription medication has become a staple in cardiovascular treatment. Though facing competition from generic alternatives, the original formulation maintains a strong reputation among patients, particularly those who may require long-term treatment.

The agreement officially takes effect from January 1, 2025, despite the renewal announcement occurring several months later. This proactive step by Navamedic reflects its strategic approach to maintaining a stable supply of Imdur, which remains one of its second-largest single-branded products.

Andersen also noted the collaborative efforts of TopRidge Pharma in updating marketing authorizations and ensuring continuous supply to the various markets where Imdur is sold. This teamwork is essential to accommodate the specific healthcare needs of each region, reaffirming Navamedic's commitment to understanding and meeting the demands of the healthcare landscape.

The renewed partnership represents not just continuity in supplying Imdur, but also a pledge to explore further opportunities for collaboration on additional products beyond the current offerings. This forward-thinking mentality positions Navamedic and TopRidge Pharma favorably in a competitive market.

Founded in 2006, Navamedic ASA has built a reputation for its reliable distribution of high-quality pharmaceutical products across the Nordics and Benelux regions. With a focus on public health concerns, including obesity, Parkinson's disease, and antibiotic treatments, the company remains dedicated to improving health outcomes by empowering patient care through strategic partnerships.

With this renewed distribution agreement, Navamedic ASA and TopRidge Pharma Limited look towards a future enriched with innovation and enhanced product offerings, ensuring that patients receive the best possible therapeutic options.

For more information, Navamedic encourages inquiries directed to:

• - Kathrine Gamborg Andreassen, CEO, Navamedic – Mobile: +47 951 78 680, Email: [email protected]
• - Lars Hjarrand, CFO, Navamedic – Mobile: +47 917 62 842, Email: [email protected]

Through initiatives like this renewal agreement, Navamedic ASA continues its journey as a trusted name in pharmaceuticals, firmly rooted in its mission to elevate the quality of life for everyone using their products. To learn more about Navamedic and their extensive portfolio, please visit Navamedic's official website.